Subscribe To
IOVA / Why Iovance Biotherapeutics Is Crashing Today
IOVA News
By GlobeNewsWire
October 31, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev more_horizontal
By Seeking Alpha
October 22, 2023
Iovance Biotherapeutics: Testing Shareholders' Patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on more_horizontal
By Seeking Alpha
October 19, 2023
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better more_horizontal
By GlobeNewsWire
September 27, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de more_horizontal
By Seeking Alpha
September 18, 2023
Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)
Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. In more_horizontal
By The Motley Fool
September 18, 2023
Why Shares of Iovance Biotherapeutics Jumped Monday
Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several more_horizontal
By The Motley Fool
September 15, 2023
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development. more_horizontal
By Invezz
September 15, 2023
IOVA stock price soared but risk/reward is unfavourable for now
Iovance Biotherapeutics (NASDAQ: IOVA) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jump more_horizontal